PARSHALL B LYNNE 4

What Happened
Lynne Parshall, a director of Cytokinetics, reported the sale of 5,000 shares on March 2, 2026. The shares were disposed at $61.21 each, for a total reported value of $306,050. This was a sale (code S) rather than a purchase or option exercise.

Key Details

• Transaction date: 2026-03-02
• Price per share: $61.21; Total proceeds: $306,050
• Transaction type: Reported as "Open market or private sale" (Form 4 sale, code S)
• Shares owned after transaction: Not specified in the provided summary — see the full Form 4 for post-transaction holdings
• Filing date: Form 4 filed 2026-03-02 (same day as the transaction in this report; no late filing indicated in the provided data)
• No 10b5-1 plan, tax-withholding, or other footnotes were provided in the summary

Context
Sales by directors are common and can reflect routine portfolio management, diversification, or other personal reasons; they do not by themselves indicate the company’s outlook. Retail investors who track insider activity often place more weight on purchases than on routine sales. For full details (post-transaction ownership, footnotes, or plan disclosures), review the complete Form 4 filing (Accession: 0001061983-26-000014).